Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 43Thoracic 5Breast 5Gastrointestinal 4CNS 3Head & Neck 2Gynecologic 2Tumor-Agnostic 1Sarcoma 1Endocrine 1

Conditions

Ovarian Neoplasms 2Recurrence 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × cabazitaxel × Gynecologic × Clear all
NCT02560337 2020-10-08

CaTo-ROC

Vejle Hospital

Phase 2 Completed
26 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT01747239 2014-12-04

Cabazitaxel in Platinum Refractory Ovarian Cancer

Vejle Hospital

Phase 2 Terminated
4 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡